News

Fierce Pharma6d
Gene therapy CDMO Artis BioSolutions launches with acquisition of Landmark Bio
Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...
Nasdaq22d
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the ...
Business Wire6d
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
yet traditionally undruggable targets with precision small-molecule therapeutics SAN DIEGO & BERLIN--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion) today announced that the first patient ...
Medical Dialogues4d
Bayer AG arm Vividion Therapeutics doses first patient in Phase I study of Inhibitor for advanced solid tumors treatment
Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating ...